Evaluation of the Pre-Posterior Distribution of Optimized Sampling Times for the Design of Pharmacokinetic Studies

Information theoretic methods are often used to design studies that aim to learn about pharmacokinetic and linked pharmacokinetic–pharmacodynamic systems. These design techniques, such as D-optimality, provide the optimum experimental conditions. The performance of the optimum design will depend on the ability of the investigator to comply with the proposed study conditions. However, in clinical settings it is not possible to comply exactly with the optimum design and hence some degree of unplanned suboptimality occurs due to error in the execution of the study. In addition, due to the nonlinear relationship of the parameters of these models to the data, the designs are also locally dependent on an arbitrary choice of a nominal set of parameter values. A design that is robust to both study conditions and uncertainty in the nominal set of parameter values is likely to be of use clinically. We propose an adaptive design strategy to account for both execution error and uncertainty in the parameter values. In this study we investigate designs for a one-compartment first-order pharmacokinetic model. We do this in a Bayesian framework using Markov-chain Monte Carlo (MCMC) methods. We consider log-normal prior distributions on the parameters and investigate several prior distributions on the sampling times. An adaptive design was used to find the sampling window for the current sampling time conditional on the actual times of all previous samples.

[1]  Andrew C. Hooker,et al.  Robust Population Pharmacokinetic Experiment Design , 2005, Journal of Pharmacokinetics and Pharmacodynamics.

[2]  Malcolm Rowland,et al.  Optimal Design for Multivariate Response Pharmacokinetic Models , 2006, Journal of Pharmacokinetics and Pharmacodynamics.

[3]  W. Näther Optimum experimental designs , 1994 .

[4]  Stephen B. Duffull,et al.  Prospective Evaluation of a D-Optimal Designed Population Pharmacokinetic Study , 2003, Journal of Pharmacokinetics and Pharmacodynamics.

[5]  Stephen Duffull,et al.  Some Considerations on the Design of Population Pharmacokinetic Studies , 2005, Journal of Pharmacokinetics and Pharmacodynamics.

[6]  L Pronzato,et al.  Optimal experiment design for nonlinear models subject to large prior uncertainties. , 1987, The American journal of physiology.

[7]  L Aarons,et al.  Design of population pharmacokinetic experiments using prior information. , 2007, Xenobiotica; the fate of foreign compounds in biological systems.

[8]  Leon Aarons,et al.  Optimum blood sampling time windows for parameter estimation in population pharmacokinetic experiments , 2006, Statistics in medicine.

[9]  J. Eccleston,et al.  Compound Optimal Design Criteria for Nonlinear Models , 2008, Journal of biopharmaceutical statistics.

[10]  D Z D'Argenio,et al.  Incorporating prior parameter uncertainty in the design of sampling schedules for pharmacokinetic parameter estimation experiments. , 1990, Mathematical biosciences.

[11]  Jean-Marie Rocchisani,et al.  Comparison of ED, EID, and API Criteria for the Robust Optimization of Sampling Times in Pharmacokinetics , 1997, Journal of Pharmacokinetics and Biopharmaceutics.

[12]  Paolo Vicini,et al.  Simultaneous population optimal design for pharmacokinetic-pharmacodynamic experiments , 2005, The AAPS Journal.

[13]  Alain Mallet,et al.  Optimal design in random-effects regression models , 1997 .

[14]  Christian P. Robert,et al.  Monte Carlo Statistical Methods , 2005, Springer Texts in Statistics.

[15]  France Mentré,et al.  Optimal Design of a Population Pharmacodynamic Experiment for Ivabradine , 2004, Pharmaceutical Research.

[16]  Gordon Graham,et al.  Optimal Design for Multiresponse Pharmacokinetic–Pharmacodynamic Models – Dealing with Unbalanced Designs , 2007, Journal of Pharmacokinetics and Pharmacodynamics.

[17]  Stephen B. Duffull,et al.  Optimal Design for Model Discrimination and Parameter Estimation for Itraconazole Population Pharmacokinetics in Cystic Fibrosis Patients , 2005, Journal of Pharmacokinetics and Pharmacodynamics.

[18]  Leon Aarons,et al.  Optimal Blood Sampling Time Windows for Parameter Estimation Using a Population Approach: Design of a Phase II Clinical Trial , 2005, Journal of Pharmacokinetics and Pharmacodynamics.

[19]  France Mentré,et al.  Further Developments of the Fisher Information Matrix in Nonlinear Mixed Effects Models with Evaluation in Population Pharmacokinetics , 2003, Journal of biopharmaceutical statistics.

[20]  David Z. D'Argenio,et al.  Optimal sampling times for pharmacokinetic experiments , 1981, Journal of Pharmacokinetics and Biopharmaceutics.

[21]  K. Chaloner,et al.  Bayesian Experimental Design: A Review , 1995 .